Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press2610.17650/2313-805X.2014.1.2.36-43REVIEWОБЗОРЫMolecular features of renal cell carcinoma: early diagnostics and perspectives for therapyМолекулярные особенности почечно-клеточного рака: ранняя диагностика и перспективы терапииKovalevaO. V.КовалеваО. В.
Russian Federation
ovkovaleva@gmail.comNazarovaO. R.НазароваО. Р.
Russian Federation
MatveevV. B.МатвеевВ. Б.
Russian Federation
GratchevA. N.ГрачевА. Н.
Russian Federation
Scientific Research Institute of Carcinogenesis, N. N. Blokhin Russian Cancer Research Center, Russia,115478, Moscow, Kashirskoye shosse, 24НИИ канцерогенеза ФГБНУ «РОНЦ им. Н. Н. Блохина», Россия, 115478, Москва, Каширское шоссе, 24Scientific Research Institute of Clinical Oncology, N. N. Blokhin Russian Cancer Research Center, Russia, 115478, Moscow, Kashirskoye shosse, 24НИИ клинической онкологии ФГБНУ «РОНЦ им. Н. Н. Блохина», Россия, 115478, Москва, Каширское шоссе, 24150520141236430306201503062015Copyright ©; 2014, Kovaleva O.V., Nazarova O.R., Matveev V.B., Gratchev A.N.Copyright ©; 2014, Ковалева О.В., Назарова О.Р., Матвеев В.Б., Грачев А.Н.2014Kovaleva O.V., Nazarova O.R., Matveev V.B., Gratchev A.N.Ковалева О.В., Назарова О.Р., Матвеев В.Б., Грачев А.Н.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/26

Kidney cancer (renal cell carcinoma) is one of the major problems of modern urological oncology. In Russia renal cell carcinoma accountsfor 4.3 % of all cancers. The global incidence of renal cell carcinoma has increased over the past two decades. Worldwide renal cell carcinoma accounts for 3.6 % of all cancers and is 10th frequent malignancy. For some malignancies, for instance tumours of prostate, there are markers known that allowed improved early diagnostics. Kidney cancer, however, remains to be hard to diagnose and to treat, since the symptoms can be detected on advanced stages of the disease. In Russia 75.4 % of renal cell carcinoma cases detected at the stage of local and locally advanced disease. Though there are various target drugs on the market aimed to treat this disease, the results of renal cell carcinoma treatment did not reach any substantial success. Most of existing target drugs for kidney cancer treatment include inhibitors of a single signalingpathway regulated by VHL1, which expression is lost in the vast majority of renal-cell carcinomas. Till now existing drugs did not reach sufficient efficacy. Therefore, it is highly important to search for new signaling pathways, regulating such cellular processes as proliferation, migration and apoptosis. Further, prognostic markers and therapy targets identified so far are not sufficient and poorly specific. Therefore identification and validation of new markers, and especially new specific targets for the treatment of kindey oncopathologies is highly important and timely task.

renal cell carcinomadiagnostic and prognostic markerstarget therapyHIF-1αVHLVEGFTGF-αPDGFBcl-2angiogenesisпочечно-клеточный ракдиагностические и прогностические маркерытаргетная терапияHIF-1αVHLVEGFTGF-αPDGFBcl-2ангиогенез1. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М. И. Давыдова, Е. М. Аксель. М.: Издательская группа РОНЦ им. Н. Н. Блохина, 2014. [Statistics of malignant neoplasms in russia and the CIS countries in 2012. M. I. avydov, E. M. Axel (eds.). Moscow, 2014. 226 p. (In Russ.)]Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М. И. Давыдова, Е. М. Аксель. М.: Издательская группа РОНЦ им. Н. Н. Блохина, 2014. [Statistics of malignant neoplasms in russia and the CIS countries in 2012. M. I. avydov, E. M. Axel (eds.). Moscow, 2014. 226 p. (In Russ.)]2. Злокачественные новообразования в России в 2008 г. Под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена, 2010. [Malignant neoplasms in Russia in 2008. V. I. Chissov, V. V. Starinskiy, G. V. Petrova (eds.). Moscow, 2010. (In Russ.)]Злокачественные новообразования в России в 2008 г. Под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена, 2010. [Malignant neoplasms in Russia in 2008. V. I. Chissov, V. V. Starinskiy, G. V. Petrova (eds.). Moscow, 2010. (In Russ.)]3. Chow W. H., Devesa S. S. Contemporary epidemiology of renal cell cancer. Cancer J 2008;14(5):288–301.Chow W. H., Devesa S. S. Contemporary epidemiology of renal cell cancer. Cancer J 2008;14(5):288–301.4. Gupta K., Miller J. D., Li J. Z. et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34(3):193–205.Gupta K., Miller J. D., Li J. Z. et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008;34(3):193–205.5. Motzer R. J., Bacik J., Murphy B. A. et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(8):289–95.Motzer R. J., Bacik J., Murphy B. A. et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(8):289–95.6. Chow W. H., Dong L. M., Devesa S. S. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7(5):245–57.Chow W. H., Dong L. M., Devesa S. S. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7(5):245–57.7. Lipworth L., Tarone R. E., McLaughlin J. K. The epidemiology of renal cell carcinoma. J Urol 2006;176(6 Pt 1):2353–8.Lipworth L., Tarone R. E., McLaughlin J. K. The epidemiology of renal cell carcinoma. J Urol 2006;176(6 Pt 1):2353–8.8. Hunt J. D., van der Hel O. L., McMillan G. P. et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005;114(1):101–8.Hunt J. D., van der Hel O. L., McMillan G. P. et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005;114(1):101–8.9. Renehan A. G., Tyson M., Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371(9612):569–78.Renehan A. G., Tyson M., Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371(9612):569–78.10. Pischon T., Lahmann P. H., Boeing H. et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118(3):728–38.Pischon T., Lahmann P. H., Boeing H. et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2006;118(3):728–38.11. Weikert S., Boeing H., Pischon T. et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008;167(4):438–46.Weikert S., Boeing H., Pischon T. et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 2008;167(4):438–46.12. Delahunt B., Thornton A. Renal cell carcinoma. A historical perspective. J Urol Pathol 1996;4:31–49.Delahunt B., Thornton A. Renal cell carcinoma. A historical perspective. J Urol Pathol 1996;4:31–49.13. Carson W. J. Solitary cysts of the kidney. Ann Surg 1928;87(2):250–6.Carson W. J. Solitary cysts of the kidney. Ann Surg 1928;87(2):250–6.14. Клиническая онкоурология. Под ред. проф. Б. П. Матвеева. М., 2011. С. 31–41. [Clinical oncourology. B. P. Matveyev (ed.). Moscow, 2011. Pp. 31–41. (In Russ.)]Клиническая онкоурология. Под ред. проф. Б. П. Матвеева. М., 2011. С. 31–41. [Clinical oncourology. B. P. Matveyev (ed.). Moscow, 2011. Pp. 31–41. (In Russ.)]15. Bodmer D., Hurk W., Groningen J. et al. Understanding familial and non-familial renal cell cancer. Hum Mol Genet 2002;11(20):2489–98.Bodmer D., Hurk W., Groningen J. et al. Understanding familial and non-familial renal cell cancer. Hum Mol Genet 2002;11(20):2489–98.16. Banks R. E., Tirukonda P., Taylor C. et al. Genetic and epigenetic analysis of von Hippel–Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66(4):2000–11.Banks R. E., Tirukonda P., Taylor C. et al. Genetic and epigenetic analysis of von Hippel–Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006;66(4):2000–11.17. Delahunt B., Eble J. N. History of the evelopment of the classification of renal cell neoplasia. Clin Lab Med 2005;25(2):231–46.Delahunt B., Eble J. N. History of the evelopment of the classification of renal cell neoplasia. Clin Lab Med 2005;25(2):231–46.18. Storkel S., Eble J. N., Adlakha K. et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer(AJCC). Cancer 1997;80(5):987–9.Storkel S., Eble J. N., Adlakha K. et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer(AJCC). Cancer 1997;80(5):987–9.19. Foster K., Prowse A., van den Berg A. et al. Somatic mutations of the von Hippel– Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3(12):2169–73.Foster K., Prowse A., van den Berg A. et al. Somatic mutations of the von Hippel– Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3(12):2169–73.20. Gnarra J. R., Tory K., Weng Y. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85–90.Gnarra J. R., Tory K., Weng Y. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85–90.21. Shuin T., Kondo K., Torigoe S. et al. Frequent somatic mutations and loss of eterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54(11):2852–5.Shuin T., Kondo K., Torigoe S. et al. Frequent somatic mutations and loss of eterozygosity of the von Hippel–Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54(11):2852–5.22. Nickerson M. L., Jaeger E., Shi Y. et al. Improved identification of von Hippel–Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14(15):4726–34.Nickerson M. L., Jaeger E., Shi Y. et al. Improved identification of von Hippel–Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14(15):4726–34.23. Maynard M. A., Ohh M. Von Hippel–Lindau tumor suppressor protein and hypoxia- nducible factor in kidney cancer. Am J Nephrol 2004;24(1):1–13.Maynard M. A., Ohh M. Von Hippel–Lindau tumor suppressor protein and hypoxia- nducible factor in kidney cancer. Am J Nephrol 2004;24(1):1–13.24. Linehan W. M., Walther M. M., Zbar B. The genetic basis of cancer of the kidney. J Urol 2003;170(6 Pt 1):2163–72.Linehan W. M., Walther M. M., Zbar B. The genetic basis of cancer of the kidney. J Urol 2003;170(6 Pt 1):2163–72.25. de Paulsen N., Brychzy A., Foumier M. C. et al. Role of transforming growth factoralpha in von Hippel–Lindau (VHL) (– / –) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98(4):1387–92.de Paulsen N., Brychzy A., Foumier M. C. et al. Role of transforming growth factoralpha in von Hippel–Lindau (VHL) (– / –) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 2001;98(4):1387–92.26. Hudes G., Carducci M., Tomczak P. et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 2007;356(22): 2271–81.Hudes G., Carducci M., Tomczak P. et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 2007;356(22): 2271–81.27. Li M., Rathmell W. K. The current status of biomarkers for renal cell carcinoma. 2011. Pр. 153–7.Li M., Rathmell W. K. The current status of biomarkers for renal cell carcinoma. 2011. Pр. 153–7.28. Zamparese R., Pannone G., Santoro A. et al. Survivin expression in renal cell carcinoma. Cancer Invest 2008;26(9):929–35.Zamparese R., Pannone G., Santoro A. et al. Survivin expression in renal cell carcinoma. Cancer Invest 2008;26(9):929–35.29. Cho D., Signoretti S., Dabora S. et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5(6): 379–85.Cho D., Signoretti S., Dabora S. et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5(6): 379–85.30. Hehlgans S., Cordes N. Caveolin-1: an essential modulator of cancer cell radioand chemoresistance. Am J Cancer Res 2011;1(4):521–30.Hehlgans S., Cordes N. Caveolin-1: an essential modulator of cancer cell radioand chemoresistance. Am J Cancer Res 2011;1(4):521–30.31. Campbell L., Jasani B., Edwards K. et al. Combined expression of caveolin-1 and an activated AKT / mTOR pathway predicts reduced disease- free survival in clinically confined renal cell carcinoma. Br J Cancer 2008;98(5):931–40.Campbell L., Jasani B., Edwards K. et al. Combined expression of caveolin-1 and an activated AKT / mTOR pathway predicts reduced disease- free survival in clinically confined renal cell carcinoma. Br J Cancer 2008;98(5):931–40.32. Vasavada S. P., Novick A. C., Williams B. R. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51(6):1057–61.Vasavada S. P., Novick A. C., Williams B. R. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51(6):1057–61.33. Uchida T., Gao J. P., Wang G. et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59(4):615–20.Uchida T., Gao J. P., Wang G. et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59(4):615–20.34. Itoi T., Yamana K., Bilim V. et al. Impact of frequent Bcl-2 expression on prognosis in renal cell carcinoma patients. Br J Cancer 2004;90(1):200–5.Itoi T., Yamana K., Bilim V. et al. Impact of frequent Bcl-2 expression on prognosis in renal cell carcinoma patients. Br J Cancer 2004;90(1):200–5.35. Rioux-Leclercq N., Turlin В., Bansard J. et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55(4):501–5.Rioux-Leclercq N., Turlin В., Bansard J. et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55(4):501–5.36. Papadopoulos I., Weichert-Jacobsen К., Wacker H. H., Sprenger E. Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study. Eur Urol 1997;31(1):49–53.Papadopoulos I., Weichert-Jacobsen К., Wacker H. H., Sprenger E. Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study. Eur Urol 1997;31(1):49–53.37. Ivanov S., Liao S. Y., Ivanova A. et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158(3):905–19.Ivanov S., Liao S. Y., Ivanova A. et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158(3):905–19.38. Dorai T., Sawczuk I., Pastorek J. et al. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest 2006;24(8):754–79.Dorai T., Sawczuk I., Pastorek J. et al. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest 2006;24(8):754–79.39. Swinson D. E., Jones J. L., Richardson D. et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in nonsmall- cell lung cancer. J Clin Oncol 2003;21(3):473–82.Swinson D. E., Jones J. L., Richardson D. et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in nonsmall- cell lung cancer. J Clin Oncol 2003;21(3):473–82.40. Maseide K., Kandel R. A., Bell R. S. et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004;10(13):4464–71.Maseide K., Kandel R. A., Bell R. S. et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004;10(13):4464–71.41. Span P. N., Bussink J., Manders P. et al. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003;89(2):271–6.Span P. N., Bussink J., Manders P. et al. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003;89(2):271–6.42. Leibovich B., Sheinin Y., Lohse C. et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007;25(30):4757–64.Leibovich B., Sheinin Y., Lohse C. et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007;25(30):4757–64.43. Rioux-Leclercq N., Fergelot P., Zerrouki S. et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38(10):1489–95.Rioux-Leclercq N., Fergelot P., Zerrouki S. et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol 2007;38(10):1489–95.44. Deprimo S. E., Bello C. L., Smeraglia J. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.Deprimo S. E., Bello C. L., Smeraglia J. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.45. Gottardo F., Liu C. G., Ferracin M. et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007;25(5):387–92.Gottardo F., Liu C. G., Ferracin M. et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007;25(5):387–92.46. Munari E., Marchionni L., Chitre A. et al. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol 2014;45(6):1130–8.Munari E., Marchionni L., Chitre A. et al. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Hum Pathol 2014;45(6):1130–8.47. Bera A., Das F., Ghosh-Choudhury N. et al. MicroRNA-21‑induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res 2014;328(1):99–117.Bera A., Das F., Ghosh-Choudhury N. et al. MicroRNA-21‑induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion. Exp Cell Res 2014;328(1):99–117.48. Qiu M., Liu L., Chen L. et al. MicroRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells. Biochem Biophys Res Commun 2014;452(1):163–9.Qiu M., Liu L., Chen L. et al. MicroRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells. Biochem Biophys Res Commun 2014;452(1):163–9.49. Li X., Xin S., He Z. et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 2014;33(6):1631–42.Li X., Xin S., He Z. et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 2014;33(6):1631–42.50. Heinzelmann J., Unrein A., Wickmann U. et al. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol 2014;21(3):1046–54.Heinzelmann J., Unrein A., Wickmann U. et al. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol 2014;21(3):1046–54.51. Fu Q., Liu Z., Pan D., Zhang W. et al. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci 2014. doi: 10.1111 / cas. 12507.Fu Q., Liu Z., Pan D., Zhang W. et al. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection. Cancer Sci 2014. doi: 10.1111 / cas. 12507.52. Zhao J. J., Chen P. J., Duan R. et al. Up- regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol 2014;7(6):3318–23.Zhao J. J., Chen P. J., Duan R. et al. Up- regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol 2014;7(6):3318–23.53. Ishihara T., Seki N., Inoguchi S. et al. Expression of the tumor suppressive miRNA-23b / 27b cluster is a good prognostic marker in clear cell renal cell carcinoma. J Urol 2014. pii: S0022–5347(14)03935–4. doi: 10.1016 /j. juro. 2014.07.001.Ishihara T., Seki N., Inoguchi S. et al. Expression of the tumor suppressive miRNA-23b / 27b cluster is a good prognostic marker in clear cell renal cell carcinoma. J Urol 2014. pii: S0022–5347(14)03935–4. doi: 10.1016 /j. juro. 2014.07.001.54. Gao C., Peng F. H., Peng L. K. MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma 2014. doi: 10.4149 / neo_2014_083.Gao C., Peng F. H., Peng L. K. MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1. Neoplasma 2014. doi: 10.4149 / neo_2014_083.55. Mc Dermott D. F., Regan M. M., Clark J. I. et al Randomized phase III trial of high-daose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastastic renal cell. J Clin Oncol 2005;23(1):133–41.Mc Dermott D. F., Regan M. M., Clark J. I. et al Randomized phase III trial of high-daose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastastic renal cell. J Clin Oncol 2005;23(1):133–41.56. Escudier B., Eisen T., Stadler W. M. et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125–34.Escudier B., Eisen T., Stadler W. M. et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125–34.57. Bellmunt J., Négrier S., Escudier B. et al. Metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009;69(1):64–72.Bellmunt J., Négrier S., Escudier B. et al. Metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 2009;69(1):64–72.58. Bellmunt J., Negrier S., Escudier B. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16–24.Bellmunt J., Negrier S., Escudier B. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(1):16–24.59. Figlin R. A., Hutson T. E., Tomczac P. et al. Overall survival with sunitinib versus interferon alfa as first-line treatment in metastatic renal-cell carcinoma. ASCO Annual Meeting Proceedings 2008. J Clin Oncol 2008;26(Suppl): 5024.Figlin R. A., Hutson T. E., Tomczac P. et al. Overall survival with sunitinib versus interferon alfa as first-line treatment in metastatic renal-cell carcinoma. ASCO Annual Meeting Proceedings 2008. J Clin Oncol 2008;26(Suppl): 5024.60. Sternberg C. N., Davis I. D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8.Sternberg C. N., Davis I. D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8.61. Larkin J. M., Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2006;60(3):216–26.Larkin J. M., Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2006;60(3):216–26.62. Keane T., Gilatt D., Evans C. P. et al. Current and future trends in the treatment of renal cancer. Eur Urol Suppl 2007;6: 374–84.Keane T., Gilatt D., Evans C. P. et al. Current and future trends in the treatment of renal cancer. Eur Urol Suppl 2007;6: 374–84.Patel P. H., Chadalavada R. S., Chaganti R. S., Motzer R. J. Targeting von Hippel–Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12(24):7215–20.63. Motzer R. J., Escudier B., Oudard S. et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372(9637):449–56.Motzer R. J., Escudier B., Oudard S. et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372(9637):449–56.64. Sosman J., Puzanov I. Combination argeted therapy in advanced renal cell carcinoma. Cancer 2009;115(10):2368–75.Sosman J., Puzanov I. Combination argeted therapy in advanced renal cell carcinoma. Cancer 2009;115(10):2368–75.65. Sternberg C. N., Bellmunt J., Grunwald V. et al. Advances in the management of etastatic renal cell cancer. Eur Urol Suppl 2009;8:758–61.Sternberg C. N., Bellmunt J., Grunwald V. et al. Advances in the management of etastatic renal cell cancer. Eur Urol Suppl 2009;8:758–61.66. Алексеев Б. Я., Калпинский А. С. Применение таргетных препаратов в лечении метастатического рака почки: последовательное назначение или комбинация. Онкоурология 2010;(4):16–23.Алексеев Б. Я., Калпинский А. С. Применение таргетных препаратов в лечении метастатического рака почки: последовательное назначение или комбинация. Онкоурология 2010;(4):16–23.[Alexeyev B. Ya., Kalpinskiy A. S. Application of target drugs in therapy of metastatic kidney cancer: sequential prescription or combination. Onkourologiya = Oncourology 2010; (4):16–23. (In Russ.)]67. NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network Web site. URL: http://www.nccn.org / professionals /physician_gls / f_guidelines.asp.NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network Web site. URL: http://www.nccn.org / professionals /physician_gls / f_guidelines.asp.68. Gowrishankar B., Ibragimova I., Zhou Y. et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 2014;15(3):329–41.Gowrishankar B., Ibragimova I., Zhou Y. et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 2014;15(3):329–41.69. Cho D. Novel targeting of phosphatidylinositol 3‑kinase and mammalian target of rapamycin in renal cell carcinoma. Cancer J 2013;19(4):311–5.Cho D. Novel targeting of phosphatidylinositol 3‑kinase and mammalian target of rapamycin in renal cell carcinoma. Cancer J 2013;19(4):311–5.